首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1886230篇
  免费   122975篇
  国内免费   17217篇
耳鼻咽喉   19796篇
儿科学   52488篇
妇产科学   53826篇
基础医学   232648篇
口腔科学   38094篇
临床医学   201812篇
内科学   430875篇
皮肤病学   41395篇
神经病学   148868篇
特种医学   80024篇
外国民族医学   74篇
外科学   275391篇
综合类   63926篇
现状与发展   106篇
一般理论   617篇
预防医学   106358篇
眼科学   33452篇
药学   104903篇
  513篇
中国医学   18095篇
肿瘤学   123161篇
  2023年   37289篇
  2022年   57896篇
  2021年   71102篇
  2020年   66279篇
  2019年   47752篇
  2018年   59885篇
  2017年   55326篇
  2016年   55107篇
  2015年   59742篇
  2014年   103485篇
  2013年   98258篇
  2012年   96443篇
  2011年   96889篇
  2010年   79456篇
  2009年   72407篇
  2008年   74485篇
  2007年   77257篇
  2006年   71501篇
  2005年   66161篇
  2004年   60613篇
  2003年   58044篇
  2002年   56203篇
  2001年   53647篇
  2000年   51949篇
  1999年   47556篇
  1998年   19660篇
  1997年   16174篇
  1996年   16135篇
  1995年   14339篇
  1994年   12047篇
  1993年   10399篇
  1992年   35658篇
  1991年   34022篇
  1990年   33282篇
  1989年   28663篇
  1988年   27304篇
  1987年   14260篇
  1986年   5901篇
  1985年   7140篇
  1984年   7898篇
  1983年   6526篇
  1982年   6552篇
  1981年   6009篇
  1980年   5582篇
  1979年   4803篇
  1978年   4601篇
  1977年   3840篇
  1976年   3489篇
  1974年   3190篇
  1973年   3013篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
  1. Download : Download high-res image (173KB)
  2. Download : Download full-size image
  相似文献   
2.
3.
目的 探讨桦木酸对大鼠肺纤维化模型肺组织中NF-κB、β-arrestin2表达的影响。方法 15只SPF级雄性SD大鼠分为对照组、模型组、桦木酸组,每组5只。对照组予以单次气管内注射1 mL·kg-1 0.9%生理盐水,模型组和桦木酸组予单次气管内快速注射5 mg·kg-1博来霉素建立大鼠肺纤维化模型。造模1天后,对照组及模型组给予10 mL·kg-1 1%可溶性淀粉溶液,桦木酸组给予50 mg·kg-1的桦木酸悬浮液,持续21天。HE、Masson染色方法观察肺组织病理改变。酶联免疫吸附法(ELISA)检测肺组织匀浆IL-6的水平。免疫组化法检测肺组织中NF-κB、β-arrestin2、IκBα的表达。结果 与对照组相比,模型组肺组织匀浆中IL-6水平升高,NF-κB、β-arrestin2、IκBα蛋白表达均上调(P<0.05)。与模型组相比,桦木酸组肺组织匀浆中IL-6水平降低,肺组织中NF-κB、β-arrestin2、IκBα蛋白表达均下调(P<0.05)。结论 桦木酸可减轻肺部炎症、减慢肺纤维化的发生发展,可能与下调肺组织中NF-κB、β-arrestin2有关。  相似文献   
4.
  1. Download : Download high-res image (243KB)
  2. Download : Download full-size image
  相似文献   
5.
6.
IntroductionDeferred treatment is a growing management strategy for low-risk prostate cancer. However, it is unknown whether this growth is mediated by patient factors. In this study, we sought to evaluate factors associated with deferred treatment in patients with low-risk prostate cancer and shifts in these factors after recent incorporation of active surveillance into national guidelines.Materials and MethodsWe identified 137,915 men diagnosed with low-risk prostate cancer (prostate-specific antigen <10 ng/mL, Gleason score ≤6, stage cT1-cT2a) in the National Cancer Database from 2010 to 2017. Multivariate logistic regression models were used to determine factors associated with deferred treatment. Interaction variables were added to determine whether trends in use of deferred treatment over time depend on race, income, education, and insurance status.ResultsThe use of deferred treatment among men with low-risk prostate cancer increased from 14.7% in 2010-2011 to 46.3% in 2016-2017 (P < .001). On multivariate analysis, deferred treatment was associated with older age, more contemporary year of diagnosis, black race, lower income, higher educational attainment, government insurance, being uninsured, treatment at an academic/research facility, and treatment at a facility in New England (each P < .05). Incorporation of interaction variables showed that black race, belonging to the two lowest income quartiles, government insurance, and being uninsured became less associated with deferred treatment in recent years.ConclusionsThe use of deferred treatment among men with low-risk prostate cancer increased significantly from 2010 to 2017. However, patients who were black, low-income, and not privately insured experienced smaller increases in deferred treatment. Interventions to increase uptake in these groups present opportunities to improve quality of care.  相似文献   
7.
  1. Download : Download high-res image (148KB)
  2. Download : Download full-size image
  相似文献   
8.
9.
PurposeTo investigate the safety and efficacy of thyroid artery embolization (TAE) in the treatment of nodular goiter (NG).MethodsDuring a 5.5-year period, 56 consecutive patients with a NG underwent TAE. In Group A, there were 20 patients with a solitary/dominant 5–11-cm nodule, and in Group B, there were 36 patients with numerous nodules. Of the 56 patients, 47 (84%) had a retrosternal goiter and 25 had hyperthyroidism. In all patients, clinical and radiological evaluations were made at baseline and 6 months after TAE, and these parameters were statistically compared.ResultsIn 56 patients, 145 of the 146 thyroid arteries were successfully embolized. The 30-day mortality rate was 1.8%. Minor and major complications occurred in 25 and 2 patients, respectively. Six months after the TAE, the mean nodule volume was reduced from 80.2 mL to 25.0 mL, the mean thyroid volume was reduced from 147.0 mL to 62.6 mL, and the mean intrathoracic extension was reduced from 31.7 mm to 15.9 mm (P < .001). Of the 22 patients with non–Graves hyperthyroidism, 19 (86%) became euthyroid. The mean thyroid-related patient-reported outcome scores improved from 155.4 to 70.4 (P < .001). Of the 51 patients, 50 (98%) declared that they would recommend TAE to other patients with NG.ConclusionsTAE is safe and effective for the treatment of NG, with a significant volume reduction of the nodule(s) and thyroid gland.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号